AbbVie Inc. Discloses Material Impairment
Ticker: ABBV · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1551152
| Field | Detail |
|---|---|
| Company | Abbvie Inc. (ABBV) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $3.5 billion, $3.6 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: impairment, disclosure
Related Tickers: ABBV
TL;DR
AbbVie flagged a big impairment charge, could be bad news.
AI Summary
On January 9, 2025, AbbVie Inc. filed an 8-K report indicating a material impairment. The filing does not specify the exact amount of the impairment or the assets affected, but it is a significant event requiring disclosure.
Why It Matters
Material impairments can signal a significant decline in the value of a company's assets, potentially impacting future earnings and investor confidence.
Risk Assessment
Risk Level: medium — Material impairments suggest a significant negative event impacting asset values, which warrants investor attention.
Key Players & Entities
- AbbVie Inc. (company) — Registrant
- January 9, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-35565 (filing_id) — SEC File Number
FAQ
What specific assets are subject to the material impairment at AbbVie Inc.?
The filing does not specify the exact assets affected by the material impairment.
What is the estimated financial impact of the material impairment on AbbVie Inc.?
The filing does not disclose the specific dollar amount of the material impairment.
When did the event triggering the material impairment occur for AbbVie Inc.?
The earliest event reported in relation to the material impairment occurred on January 9, 2025.
Is this material impairment related to a specific business segment or product line of AbbVie Inc.?
The filing does not provide details on whether the impairment is tied to a specific segment or product.
What is the reason behind the material impairment at AbbVie Inc.?
The filing does not state the specific reasons for the material impairment.
Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2025-01-10 08:31:46
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange
- $3.5 billion — sset impairment charge of approximately $3.5 billion. AbbVie continues to evaluate informa
- $3.6 billion — ning intangible assets of approximately $3.6 billion. SIGNATURE Pursuant to the requirem
Filing Documents
- abbv-20250109.htm (8-K) — 37KB
- 0001551152-25-000006.txt ( ) — 239KB
- abbv-20250109.xsd (EX-101.SCH) — 4KB
- abbv-20250109_def.xml (EX-101.DEF) — 19KB
- abbv-20250109_lab.xml (EX-101.LAB) — 35KB
- abbv-20250109_pre.xml (EX-101.PRE) — 20KB
- abbv-20250109_htm.xml (XML) — 8KB
06 Material Impairments
Item 2.06 Material Impairments On January 9, 2025, AbbVie determined that it will record an impairment charge related to the emraclidine intangible asset acquired as part of the acquisition of Cerevel Therapeutics Holdings, Inc. On November 11, 2024, AbbVie announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms, did not meet their primary endpoint of showing a statistically significant reduction (improvement) in the change from baseline in the Positive and Negative Syndrome Scale total score compared to the placebo group at week 6. Following the results of these trials, AbbVie began an evaluation of the emraclidine intangible asset for impairment which resulted in a significant decrease in the estimated future cash flows for the product. Based on the revised cash flows, the company estimates a non-cash after-tax intangible asset impairment charge of approximately $3.5 billion. AbbVie continues to evaluate information with respect to the Cerevel-related clinical development programs and will monitor the remaining intangible assets of approximately $3.6 billion. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: January 10, 2025 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer